On the 10th, Ildong Holding’s new drug development subsidiary Idience announced that its IND(Investigational New Drug) application for ‘Venadaparib (IDX-1197)’ for gastric cancer patients was approved by China’s National Medical Products Administration.

Venadaparib, a PARP (ADP-ribose polymerase) inhibitor, is a new targeted therapy candidate that is being developed to target breast cancer, ovarian cancer, gastric cancer, and PARP inhibitor-resistant cancers.

Idience plans to evaluate the safety and efficacy of Venadaparib in combination with irinotecan, an established anticancer drug, on gastric cancer patients in China as soon as all the requirements are met.

Idience